ADMA Adma Biologics Inc

Price (delayed)

$1.73

Market cap

$221.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.78

Enterprise value

$253.53M

Sector: Healthcare
Industry: Biotechnology

Highlights

ADMA's gross margin is up by 35% QoQ and by 2.6% YoY
ADMA's revenue is up by 33% year-on-year and by 14% since the previous quarter
ADMA's quick ratio has shrunk by 53% YoY but it is up by 5% QoQ
The gross profit has contracted by 30% YoY but it has grown by 26% from the previous quarter
The company's net income fell by 38% YoY

Key stats

What are the main financial stats of ADMA
Market
Shares outstanding
128.19M
Market cap
$221.77M
Enterprise value
$253.53M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.86
Price to sales (P/S)
4.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.27
Earnings
Revenue
$48.07M
EBIT
-$62.42M
EBITDA
-$58.04M
Free cash flow
-$123.81M
Per share
EPS
-$0.78
Free cash flow per share
-$1.07
Book value per share
$0.93
Revenue per share
$0.42
TBVPS
$1.99
Balance sheet
Total assets
$235.67M
Total liabilities
$123.16M
Debt
$93.73M
Equity
$112.5M
Working capital
$156.07M
Liquidity
Debt to equity
0.83
Current ratio
8.36
Quick ratio
3.65
Net debt/EBITDA
-0.55
Margins
EBITDA margin
-120.7%
Gross margin
-29.5%
Net margin
-155.8%
Operating margin
-131.7%
Efficiency
Return on assets
-36.3%
Return on equity
-85.8%
Return on invested capital
-29.1%
Return on capital employed
-29.1%
Return on sales
-129.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADMA stock price

How has the Adma Biologics stock price performed over time
Intraday
0.58%
1 week
3.59%
1 month
4.85%
1 year
-33.97%
YTD
-11.28%
QTD
-1.7%

Financial performance

How have Adma Biologics's revenue and profit performed over time
Revenue
$48.07M
Gross profit
-$14.16M
Operating income
-$63.31M
Net income
-$74.88M
Gross margin
-29.5%
Net margin
-155.8%
Adma Biologics's operating income has decreased by 41% YoY but it has increased by 2.5% QoQ
The company's net income fell by 38% YoY
ADMA's gross margin is up by 35% QoQ and by 2.6% YoY
ADMA's revenue is up by 33% year-on-year and by 14% since the previous quarter

Growth

What is Adma Biologics's growth rate over time

Valuation

What is Adma Biologics stock price valuation
P/E
N/A
P/B
1.86
P/S
4.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.27
The EPS has grown by 11% since the previous quarter and by 10% year-on-year
The price to book (P/B) is 70% lower than the 5-year quarterly average of 6.2 and 26% lower than the last 4 quarters average of 2.5
The equity has increased by 27% since the previous quarter and by 17% year-on-year
ADMA's price to sales (P/S) is 42% lower than its 5-year quarterly average of 7.2 and 18% lower than its last 4 quarters average of 5.1
ADMA's revenue is up by 33% year-on-year and by 14% since the previous quarter

Efficiency

How efficient is Adma Biologics business performance
ADMA's ROE is up by 19% YoY and by 6% QoQ
The return on sales has grown by 14% since the previous quarter but it has declined by 6% year-on-year
The company's return on invested capital rose by 8% QoQ but it fell by 4.3% YoY
The company's return on assets rose by 4.2% QoQ but it fell by 3.1% YoY

Dividends

What is ADMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADMA.

Financial health

How did Adma Biologics financials performed over time
Adma Biologics's total assets is 91% more than its total liabilities
ADMA's quick ratio has shrunk by 53% YoY but it is up by 5% QoQ
ADMA's current ratio is down by 30% YoY but it is up by 8% QoQ
The company's debt is 17% lower than its equity
The equity has increased by 27% since the previous quarter and by 17% year-on-year
Adma Biologics's debt to equity has decreased by 22% QoQ and by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.